한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제41권3호
  • /
  • Pages.165-169
  • /
  • 2024
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

Transient Non-Regenerative Anemia in a Dog with Granulomatous Meningoencephalitis Following Leflunomide Treatment

  • Ga-Hyun Lim (Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University) ;
  • Ju-Hyun An (Department of Veterinary Emergency and Critical Care Medicine, College of Veterinary Medicine, Kangwon National University) ;
  • Su-Min Park (Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University) ;
  • Jeong-Hwa Lee (Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University) ;
  • Ye-In Oh (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University) ;
  • Kyoung-Won Seo (Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University) ;
  • Hwa-Young Youn (Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University)
  • 투고 : 2024.05.27
  • 심사 : 2024.06.12
  • 발행 : 2024.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A 10-year-old, spayed female Maltese dog was tentatively diagnosed with granulomatous meningoencephalitis (GME) on magnetic resonance imaging. The meningoencephalitis was classified as aseptic GME because cerebral fluid analysis did not reveal an infectious aetiology. Two months after leflunomide treatment (Arava; Sanofi; 4 mg/kg/day), the patient developed non-regenerative, macrocytic, and normochromic anemia. As the patient's anaemia began after the administration of leflunomide, and other differentials for anaemia had been ruled out, the leflunomide was determined to be the cause and this treatment ended. After 15 days, the anaemia resolved spontaneously. This is the first report of reversible aplastic anaemia following treatment with leflunomide in a canine patient with GME.

키워드

과제정보

This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (RS-2023-00240708).

참고문헌

  1. Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004; 38: 1206-1211.  https://doi.org/10.1345/aph.1E012
  2. Chan V, Tett SE. How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting. Pharmacoepidemiol Drug Saf 2006; 15: 485-493.  https://doi.org/10.1002/pds.1252
  3. Colopy SA, Baker TA, Muir P. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). J Am Vet Med Assoc 2010; 236: 312-318.  https://doi.org/10.2460/javma.236.3.312
  4. Fukushima K, Eguchi N, Ohno K, Kanemoto H, Takahashi M, Igarashi H, et al. Efficacy of leflunomide for treatment of refractory inflammatory colorectal polyps in 15 miniature dachshunds. J Vet Med Sci 2016; 78: 265-269.  https://doi.org/10.1292/jvms.15-0129
  5. Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015; 373: 1649-1658.  https://doi.org/10.1056/NEJMra1508861
  6. Jung JH, Yang Y, Seo D, Cho S, Choi G, Kim Y. Clinical utility of immature reticulocyte fraction for identifying early red blood cell regeneration in anemic dogs. J Vet Intern Med 2023; 37: 484-489.  https://doi.org/10.1111/jvim.16641
  7. Koller G, Cusnir I, Hall J, Ye C. Reversible alopecia areata: a little known side effect of leflunomide. Clin Rheumatol 2019; 38: 2015-2016.  https://doi.org/10.1007/s10067-019-04577-3
  8. Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv Hematol 2009; 2009: 495863. 
  9. Park SY, Back SY, Park SW, Kim JH, Son CN, Cho SK, et al. Hemolytic anemia in a patient with rheumatoid arthritis treated with leflunomide. J Korean Soc Clin Pharmacol Ther 2008; 16: 87-91.  https://doi.org/10.12793/jkscpt.2008.16.2.87
  10. Sato M, Veir JK, Legare M, Lappin MR. A retrospective study on the safety and efficacy of leflunomide in dogs. J Vet Intern Med 2017; 31: 1502-1507.  https://doi.org/10.1111/jvim.14810
  11. Toyokawa Y, Kingetsu I, Yasuda C, Yasuda J, Yoshida K, Kurosaka D, et al. Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. Mod Rheumatol 2007; 17: 436-440.  https://doi.org/10.3109/s10165-007-0613-8
  12. van der Heijden EH, Hartgring SA, Kruize AA, Radstake TR, van Roon JA. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjogren's syndrome. Expert Rev Clin Immunol 2019; 15: 801-808.  https://doi.org/10.1080/1744666X.2019.1624527
  13. van Riel PL, Smolen JS, Emery P, Kalden JR, Dougados M, Strand CV, et al. Leflunomide: a manageable safety profile. J Rheumatol 2004; 71: 21-24. 
  14. Wusthof M, Smirnova A, Bacher U, Kroger N, Zander AR, Schuch G, et al. Severe aplastic anaemia following leflunomide therapy. Rheumatology (Oxford) 2010; 49: 1016-1017. https://doi.org/10.1093/rheumatology/kep406